NCT05511870 - A Study of Etripamil in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 7, 2023

Primary Completion Date

March 26, 2023

Study Completion Date

March 26, 2023

Conditions

Healthy Chinese Subjects

Interventions

DRUG

Etripamil Nasal Spray 70mg

Etripamil NS 70 mg will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.

DRUG

Placebo

Placebo will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.

Trial Locations (1)

Unknown

Huashan Hospital Affiliated to Fudan University, Shanghai